As previously discussed, the necessity for administering supplementary ESAs is critical to compensate for the insufficient endogenous erythropoietin in CKD patients, which complicates the stabilization of Hb levels [6, 9–11]. This evidence concerns the gene EPO and chronic kidney disease.